1-3 of 3
Gavin Lewis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A UK Cost-Effectiveness Analysis Comparing First Line Treatment with Rituximab in Combination with Fludarabine and Cyclophosphamide Versus Fludarabine and Cyclophosphamide Alone in Chronic Lymphocytic Leukemia (CLL) Patients

Konstantinos Papadakis, MSc, David Oscier, Emma SC Carr, BSc, MSc, PhD, Gavin Lewis, Rick Aultman, MSc, Stats
Journal: Blood
Blood (2008) 112 (11): 2392.
https://doi.org/10.1182/blood.V112.11.2392.2392
Published: 2008
Journal Articles

Cost Effectiveness of Rituximab Maintenance (R-Maint) vs Autologous Stem Cell Transplant (ASCT) from a UK National Health Service (NHS) Perspective.

Douglas R. Millar, BA (Hons), Gavin Lewis, MSc, Robert Marcus, MBBS FRCP FRCPath
Journal: Blood
Blood (2007) 110 (11): 3321.
https://doi.org/10.1182/blood.V110.11.3321.3321
Published: 2007
Journal Articles

The Cost-Effectiveness of Rituximab, Cyclophosphamide, Vincristine and Prednisolone (RCVP) Compared with CVP for the Treatment of Follicular Non-Hodgkin’s Lymphoma (NHL) in the UK.

Gavin Lewis, MSc, Robert E. Marcus, MB, Stephen J. Proctor, FRCP FRCPath, Marlene Gyldmark, James Creeden, MD PhD, Rick Aultman, MSc, Fred Jost, MSc
Journal: Blood
Blood (2006) 108 (11): 345.
https://doi.org/10.1182/blood.V108.11.345.345
Published: 2006